Payment overview · 2025
General Payments
$37.22
2 reported records · 2 companies
Healthcare provider profile · identity verified
Kelli Windsor, DO
Allopathic & Osteopathic Physicians|Family Medicine · BRECKENRIDGE, TX · NPI 1104246057
Verified facts
What the public records show
CMS Open Payments records show Kelli Windsor, DO received $37.22 in general payments during 2025 across 2 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 53.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.82 | 53.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $17.40 | 46.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $37.22 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.82 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $17.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 426 | 121 |
| Levothyroxine Sodium | Levothyroxine Sodium | 329 | 75 |
| Gabapentin | Gabapentin | 252 | 63 |
| Amlodipine Besylate | Amlodipine Besylate | 237 | 65 |
| Losartan Potassium | Losartan Potassium | 232 | 62 |
| Lisinopril | Lisinopril | 231 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 184 | 51 |
| Furosemide | Furosemide | 158 | 48 |
| Omeprazole | Omeprazole | 149 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 140 | 34 |
| Metformin Hcl | Metformin Hcl | 137 | 40 |
| Montelukast Sodium | Montelukast Sodium | 132 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 128 | 39 |
| Potassium Chloride | Potassium Chloride | 125 | 37 |
| Famotidine | Famotidine | 119 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 118 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 106 | 31 |
| Eliquis | Apixaban | 104 | 21 |
| Ozempic | Semaglutide | 103 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 95 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 93 | 25 |
| Trazodone Hcl | Trazodone Hcl | 91 | 20 |
| Tramadol Hcl | Tramadol Hcl | 90 | 24 |
| Allopurinol | Allopurinol | 89 | 16 |
| Carvedilol | Carvedilol | 89 | 26 |
| Pregabalin | Pregabalin | 88 | 18 |
| Buspirone Hcl | Buspirone Hcl | 86 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 85 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 79 | 23 |
| Metformin Hcl Er | Metformin Hcl | 68 | 22 |
| Meloxicam | Meloxicam | 67 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 67 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 62 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 62 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 62 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 61 | 35 |
| Oxycodone Hcl | Oxycodone Hcl | 58 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | 12 |
| Ondansetron Odt | Ondansetron | 54 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 53 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 52 | 16 |
| Mounjaro | Tirzepatide | 51 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 50 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 49 | 12 |
| Prednisone | Prednisone | 49 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | 13 |
| Sucralfate | Sucralfate | 48 | 13 |
| Alendronate Sodium | Alendronate Sodium | 46 | 13 |
| Spironolactone | Spironolactone | 46 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 45 | suppressed |
| Celecoxib | Celecoxib | 44 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 44 | 15 |
| Clonazepam | Clonazepam | 41 | suppressed |
| Jardiance | Empagliflozin | 41 | 12 |
| Naproxen | Naproxen | 41 | suppressed |
| Simvastatin | Simvastatin | 41 | 12 |
| Finasteride | Finasteride | 38 | suppressed |
| Cephalexin | Cephalexin | 36 | 25 |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 35 | 11 |
| Topiramate | Topiramate | 35 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Mirtazapine | Mirtazapine | 34 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Methocarbamol | Methocarbamol | 31 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 30 | suppressed |
| Clotrimazole | Clotrimazole | 29 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Linzess | Linaclotide | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Hydrocortisone | Hydrocortisone | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Mupirocin | Mupirocin | 22 | 14 |
| Creon | Lipase/Protease/Amylase | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Metronidazole | Metronidazole | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 13 |
| Cefdinir | Cefdinir | 14 | 14 |
| Ciclopirox | Ciclopirox | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Prolia | Denosumab | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Zaleplon | Zaleplon | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $37.22 · 2 records | Bayer Healthcare Pharmaceuticals Inc. | Kerendia, WATCHMAN FLX | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error